Helping mid-sized MedTech companies win the future
Time to act is now: regulatory pressure, margin squeeze, and the race for operational excellence
Europe remains the second-largest MedTech market globally, with steady 5.4% annual growth over the past decade. However, the sector is entering a period of profound change, facing unprecedented margin pressures and regulatory complexity that has disproportionately large impact on smaller players.
Implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has fundamentally reshaped the competitive landscape, creating significant barriers for emerging companies. Simultaneously, healthcare systems across Europe are tightening procurement budgets as population age and healthcare spending rises. Manufacturing costs continue to escalate, while vulnerabilities across global sourcing and manufacturing networks are increasing.
As a result, mid-sized MedTech companies need to look towards rationalising portfolios, strengthening compliance infrastructure, and improving operational resilience while continuing to compete against larger multinationals with greater scale and resources.
Key industry trends shaping mid-size MedTech strategy
- Geopolitical configuration and supply chain agility
Tariff risks and geopolitical uncertainty are making strategic supply chain design and reviews necessary. While larger players are reshoring to the US, smaller companies should focus on geographic supplier diversification and near-shoring strategies tailored to their scale. Building supply chain flexibility and resilience - rather than pursuing capital-intensive reshoring is the pragmatic path for mid-sized companies. - Operational efficiency as a competitive imperative
Mid-sized MedTech companies must simplify their operations and standardise to safeguard profitability. This includes consolidating vendor bases, rationalising product portfolios and implementing regional logistic and support models to enhance supply chain resilience. For mid-sized companies with limited capital, focusing on quick wins such as e-commerce platform consolidation and e-invoicing solutions-can deliver immediate cost benefits while building the momentum for broader transformation. - Digital transformation and data-driven decision-making
The MedTech sector lags behind other industries in adopting digital solutions and AI for internal operations. Mid-sized companies should prioritise data infrastructure readiness and systems integration while being bold on implementing 2-3 tangible AI use cases.
Predictive analytics for inventory management and supplier reliability assessment are already delivering tangible benefits. Process and task mining offer cost-effective pathways to identify operational inefficiencies without require massive IT overhauls. But the challenge remains the same: how to integrate these technologies despite risk-averse organisational cultures that prioritise regulatory compliance and patient safety.
- Sustainability and decarbonisation as market differentiators
Environmental responsibility is increasingly embedded in MedTech improvement roadmaps, driven by the UN Sustainable Development Goals and regulatory mandates. For mid-sized companies, proactively addressing sustainability becomes a true differentiator when it also delivers measurable business impact through growth, profitability, or customer preference. Strategic investments in product sustainability and decarbonisation position these organisations to meet healthcare provider sustainability requirements while also generating tangible returns.
How we can help
From growth strategy to AI, sustainability, and health economics, explore six key building blocks that can help organisations navigate transformation and create measurable business value. We combine deep industry knowledge with practical implementation experience and find actionable outcomes that can address complex challenges successfully.
